Analysts Offer Predictions for CMPX Q1 Earnings

Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) - Analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Compass Therapeutics in a report released on Thursday, February 27th. HC Wainwright analyst J. Pantginis forecasts that the company will earn ($0.11) per share for the quarter. HC Wainwright has a "Buy" rating and a $10.00 price target on the stock. The consensus estimate for Compass Therapeutics' current full-year earnings is ($0.36) per share. HC Wainwright also issued estimates for Compass Therapeutics' Q2 2025 earnings at ($0.12) EPS, Q3 2025 earnings at ($0.13) EPS, Q4 2025 earnings at ($0.07) EPS and FY2028 earnings at $0.85 EPS.

A number of other equities research analysts have also recently weighed in on CMPX. Jefferies Financial Group upped their price target on Compass Therapeutics from $7.00 to $8.00 and gave the stock a "buy" rating in a report on Monday, February 10th. Piper Sandler initiated coverage on Compass Therapeutics in a report on Wednesday, February 19th. They issued an "overweight" rating and a $12.00 target price on the stock. Leerink Partnrs cut Compass Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Friday, November 15th. Guggenheim initiated coverage on shares of Compass Therapeutics in a research report on Monday, February 24th. They issued a "buy" rating and a $12.00 price objective on the stock. Finally, Leerink Partners downgraded shares of Compass Therapeutics from an "outperform" rating to a "market perform" rating and dropped their target price for the company from $5.00 to $4.00 in a report on Friday, November 15th. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $11.38.

Compass Therapeutics Stock Performance

CMPX traded down $0.17 on Monday, hitting $2.73. 1,057,268 shares of the company were exchanged, compared to its average volume of 1,931,967. The business's fifty day moving average is $2.59 and its 200 day moving average is $1.96. Compass Therapeutics has a fifty-two week low of $0.76 and a fifty-two week high of $4.08. The firm has a market capitalization of $375.62 million, a P/E ratio of -7.38 and a beta of 1.17.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.11) earnings per share for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.01).

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Rovin Capital UT ADV acquired a new position in shares of Compass Therapeutics in the third quarter valued at approximately $25,000. Tower Research Capital LLC TRC grew its stake in Compass Therapeutics by 298.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 17,251 shares of the company's stock worth $25,000 after acquiring an additional 12,917 shares during the period. Independent Advisor Alliance acquired a new position in Compass Therapeutics in the 4th quarter valued at $26,000. BNP Paribas Financial Markets purchased a new position in shares of Compass Therapeutics during the 4th quarter worth $27,000. Finally, Intech Investment Management LLC acquired a new stake in shares of Compass Therapeutics during the third quarter worth $30,000. 68.43% of the stock is currently owned by hedge funds and other institutional investors.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.